Enzymes are nature's tiny powerhouses, helping with everything from digesting food to making it quicker and safer to produce ...
Researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology—an emerging technology that uses ...
PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant ...
Scientists created a definitive E3 ligase atlas, resolving inconsistencies and enabling better disease research and drug ...
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
Now, following up on that success, a large Chinese collaboration has followed up with a description of an improved gene ...
A fat-producing enzyme in brain cells may play a key role in driving damage in Parkinson's disease and could offer a new ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...
GAITHERSBURG, Md., April 08, 2026 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics, a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in ...
A study led by Qun-Ying Lei shows that PGG inhibits the MAT2A enzyme activity while simultaneously promoting its degradation.
A precision cancer strategy that selectively kills tumour cells while leaving healthy tissue intact may be within reach for the majority of colorectal cancer patients, according to new research ...
A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results